January 2022: Cannabis Use and the Endocannabinoid System

January 2022: Cannabis Use and the Endocannabinoid System

In this month's AJP Audio, Dr Margert Haney (Director of the Cannabis Research Laboratory at Columbia Psychiatry) discusses her new review from the January issue of the American Journal of Psychiatry, "Cannabis Use and the Endocannabinoid System: A Clinical Perspective," and the questions around the legal status of cannabis research. Afterward, Dr. Ned Kalin, Editor-in-Chief of the Journal discusses the January 2022 issue of AJP.

  • Haney interview: How does cannabis interact with our brains? [00:30]
  • CBD and how it's different [01:26]
  • Impact of state legalization of cannabis on research [02:08]
  • Federal attitudes towards cannabis legalization [03:43]
  • A single source of cannabis for research [04:57]
  • Limitations on research and an expanding, unexamined market [06:11]
  • Marketing of other cannabinoids [06:38]
  • Consequences of cannabis legalization [08:06]
  • Cannabis use disorder [08:36]
  • What happens with daily cannabis use – and abrupt cessation? [09:27]
  • What happens to your endocannabinoid system with daily use? [10:36]
  • A proliferating market and constrained research [11:56]
  • Patients foregoing FDA-approved medication in favor of cannabis products [12:14]
  • There's a reason we have randomized controlled clinical trials with placebo [12:37]
  • Changes in cannabis use and abuse [13:31]
  • Public perception of cannabis use disorder [14:26]
  • What's next for cannabis research? [15:20]
  • Loosening of cannabis sources [16:03]
  • No US source for CBD to study [16:36]
  • Future changes in the status quo? [17:24]
  • Importance of the endogenous cannabinoid system [18:41]
  • Potential consequences during vulnerable times in brain development: in utero and adolescence [19:08]
  • Marketing cannabis to pregnant women [19:45]
  • Kalin interview [20:30]
  • Alcohol and cannabis use disorders [20:39]
  • Haney [21:43]
  • Browne et al. [22:34]
  • Livne et al. [23:31]
  • Mellentin et al. [25:38]
  • Mallard et al. [27:39]
  • In sum [28:30]

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Stitcher, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(224)

September 2026: Circadian Rhythm Stabilization App to Prevent Mood Episode Recurrence in Patients With Mood Disorders: A Multicenter, Double-Blind, Sham-Controlled, Randomized Clinical Trial

September 2026: Circadian Rhythm Stabilization App to Prevent Mood Episode Recurrence in Patients With Mood Disorders: A Multicenter, Double-Blind, Sham-Controlled, Randomized Clinical Trial

Dr. Heon-Jeong Lee (Korea University, Seoul) joins AJP Audio to discuss an app-based intervention designed to help individuals with mood disorders regulate their circadian rhythms to prevent recurre...

1 Syys 29min

August 2026: Cognitive, Electrophysiological, and Behavioral Presentation of First-Episode Psychosis With or Without Cannabis Exposure

August 2026: Cognitive, Electrophysiological, and Behavioral Presentation of First-Episode Psychosis With or Without Cannabis Exposure

Dr. Deepak Cyril D'Souza (Yale University School of Medicine) joins the podcast to discuss a study looking at two cohorts of patients hospitalized with first instances of psychosis, one with cannabis ...

1 Elo 33min

July 2026: Social Determinants of Health in Psychiatric Disorders: Exciting Opportunities for Biopsychosocial Research and Clinical Care

July 2026: Social Determinants of Health in Psychiatric Disorders: Exciting Opportunities for Biopsychosocial Research and Clinical Care

Dr. Dilip Jeste (Social Determinants of Health Network, La Jolla, CA) joins the podcast to discuss how social determinants of health interact with treatment for psychiatric disorders.  Afterwards, AJP...

1 Heinä 37min

June 2026: Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

June 2026: Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

Dr. Jason Tucciarone and Dr. Alan Schatzberg (Stanford University, Stanford, CA) join AJP Audio to discuss the use of low-dose buprenorphine as an adjunctive therapy to extend the anti-suicidal effec...

1 Kesä 29min

Special Episode: The Future of DSM

Special Episode: The Future of DSM

In this special episode of AJP Audio, AJP Editor-in-Chief Dr. Ned Kalin is joined by Dr. María Oquendo (Perelman School of Medicine at the University of Pennsylvania, Philadelphia), chair of APA's Fut...

15 Touko 22min

May 2026: Psychiatric Comorbidities in Substance Use Disorders: Sex-Based Differences in a National Real-World Clinical Sample

May 2026: Psychiatric Comorbidities in Substance Use Disorders: Sex-Based Differences in a National Real-World Clinical Sample

Dr. Eduardo Butelman (Icahn School of Medicine at Mount Sinai, New York) joins AJP Audio to discuss the varying incidence of psychiatric comorbidities across patients diagnosed with substance use diso...

1 Touko 30min

April 2026: Mobile Health for Alcohol Use Assessment: Longitudinal Effects of Breathalyzer Self-Monitoring in Everyday Contexts

April 2026: Mobile Health for Alcohol Use Assessment: Longitudinal Effects of Breathalyzer Self-Monitoring in Everyday Contexts

Yang Lu, M.S., and Catharine E. Fairbairn, Ph.D. (University of Illinois, Urbana-Champaign) join AJP Audio to discuss the longitudinal effects of the use of personal alcohol breathalyzers in a natural...

1 Huhti 35min

March 2026: Primary Prevention of PTSD Symptoms in Combat-Deploying Soldiers Using Attention Bias Modification: A Randomized Controlled Trial

March 2026: Primary Prevention of PTSD Symptoms in Combat-Deploying Soldiers Using Attention Bias Modification: A Randomized Controlled Trial

Chelsea Dyan Gober Dykan, M.A. (Tel Aviv University, Israel), joins AJP Audio to discuss a study looking at two versions of attention bias modification with an eye towards a prophylactic impact on dev...

1 Maalis 33min

Suosittua kategoriassa Tiede

utelias-mieli
rss-mita-tulisi-tietaa
tiedekulma-podcast
rss-poliisin-mieli
rss-duodecim-lehti
rss-hereilla
rss-luontopodi-samuel-glassar-tutkii-luonnon-ihmeita
mielipaivakirja
rss-miljonaarien-tasavalta
rss-politiikasta-podcast
rss-lihavuudesta-podcast
docemilia